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Abstract We describe a new chicken P2X subunit that is an
orthologue of the mammalian P2X1 receptor. Functional char-
acterization of chicken P2X1 receptors was performed using the
amphotericin B perforated patch con¢guration to avoid the cur-
rent run-down observed under whole-cell patch-clamp condi-
tions. Responses to agonists and to the antagonist PPADS
(pyridoxal 5-phosphate 6-azophenyl-2P,4P-disulfonic acid) were
similar to what has been described for mammalian orthologues.
However, the antagonists suramin and NF023 were much less
potent at chicken P2X1 receptors than at human P2X1 recep-
tors. In embryonic tissues, transcript expression is predominant
in lung, liver and skeletal muscle. Overlapping expression with
cP2X4 and cP2X5 subunits in several embryonic tissues, includ-
ing skeletal muscle, indicates that the native embryonic P2X
receptors could be heteromultimeric.
3 2002 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Extracellular ATP exerts its biological e¡ects by binding to
two di¡erent types of membrane receptors, P2X and P2Y
receptors. P2X receptors are ligand-gated ion channels of
which seven subunits have been cloned from mammalian tis-
sues [1]. Several non-mammalian orthologues of P2X receptor
subunits have been isolated and functionally characterized
including zebra¢sh P2X3 [2,3], zebra¢sh [4], chicken [5,6]
and Xenopus laevis [7] P2X4, zebra¢sh [4], chicken [8,9] and
bull-frog [10] P2X5 and X. laevis [11] P2X7. In most cases,
di¡erences in the pharmacological and/or functional proper-
ties between mammalian and non-mammalian orthologue
P2X receptors have been described.
P2X1 receptor subunits were initially isolated from rat vas
deferens by expression cloning [12]. The protein and mRNA
show a wide distribution in rat tissues, although the highest
levels of expression are found in smooth muscle containing
tissues [13]. Indication that the native smooth muscle P2X
receptor is mainly composed of P2X1 subunits has been ob-
tained by comparing the functional properties of native and
heterologously expressed P2X1 receptors [12,14] and by
knocking out the P2X1 gene [15]. P2X1 subunit orthologues
have been isolated from human urinary bladder and mouse
vas deferens [16]. Homomeric mammalian P2X1 receptors are
rapidly desensitizing, K,L methylen-ATP (KLmeATP) sensitive
receptors that are e¡ectively blocked by suramin and suramin
derivatives, pyridoxal 5-phosphate 6-azophenyl-2P,4P-disul-
fonic acid (PPADS) and trinitrophenyl-ATP (TNP-ATP) [16].
Responses to ATP have been demonstrated in embryonic
skeletal muscle. Hume’s group showed that ATP elicits a de-
velopmentally regulated depolarizing action on cultured chick
myotubes [17]. There are indications that P2X receptors might
also be involved in mammalian skeletal muscle development.
Thus, P2X2, P2X5 and P2X6 subunits are sequentially ex-
pressed in developing rat muscle [18] and responses to ATP
have been reported in isolated mouse and human skeletal
muscle cells during pre- and postnatal myogenesis [19,20]. In
order to isolate P2X subunits from chicken embryos and to
characterize their distribution and putative function during
development, partial sequences of P2X receptor subunits ex-
pressed in chicken embryos were ampli¢ed using degenerate
PCR. We have already described at the molecular level two
chicken P2X receptor subunits: chicken P2X4 (cP2X4) [5] and
chicken P2X5 (cP2X5) [9]. Both transcripts are present in de-
veloping skeletal muscle [6,9] and the cP2X5 receptor is in-
volved in the di¡erentiation of satellite cells in mature muscle
¢bers [21]. Here we present the cloning and characterization
of the third isolated chicken P2X subunit. The strong similar-
ity with the already cloned P2X1 subunits indicates that chick-
en P2X1 (cP2X1) is the ¢rst P2X1 orthologue of non-mamma-
lian origin. The overlapping expression with other P2X
transcripts in several embryonic tissues including skeletal
muscle strongly supports the presence of a heteromultimeric
P2X receptor during development.
2. Materials and methods
2.1. Isolation of the cP2X1 cDNA
A partial cDNA for the cP2X1 subunit was obtained from chicken
brain poly(A)þ mRNA using degenerate PCR as previously described
[22]. Speci¢c sense (5P-GGACAGTTCTTTTGTGGTGATGAC-3P)
and antisense (5P-GAAGGTGATGCTGTTCT TGATGAA-3P) oligo-
nucleotides targeted to the known sequence of cP2X1 were extended
by PCR (Expand long template PCR system, Roche Biosciences, Palo
Alto, CA, USA) towards the 5P and 3P mRNA ends. As templates, we
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used libraries of adaptor-ligated cDNA constructed following manu-
facturer’s recommendations (Marathon cDNA ampli¢cation kit, BD
Biosciences Clontech, Palo Alto, CA, USA) from 14-day-old chicken
embryo skeletal muscle or heart poly(A)þ mRNA. Fragments ob-
tained from the PCR were cloned in pGEM-T (Promega, Madison,
WI, USA) and sequenced. To obtain a full-length coding sequence,
speci¢c oligonucleotides were used to amplify an embryonic heart
cDNA by PCR (PfuTurbo DNA polymerase, Stratagene, La Jolla,
CA, USA). To avoid random mutations arising from the PCR,
DNA fragments from independent reactions were cloned and se-
quenced.
2.2. Northern blot analysis
Poly(A)þ mRNAs were isolated from tissues obtained from 15-day-
old chicken embryos using the FastTrack Kit 2.0 (Invitrogen, Gro-
ningen, The Netherlands). The concentration of RNA in each sample
was determined using the Ribogreen RNA quantitation kit (Molec-
ular Probes, Leiden, The Netherlands). Ten micrograms poly(A)þ
RNA per tissue were separated in a 1% agarose gel containing form-
aldehyde, capillary transferred onto a positively charged nylon mem-
brane (Roche Biosciences, Palo Alto, CA, USA) and UV-crosslinked.
The membrane was hybridized with a [K-32P]dCTP labeled probe
containing the complete coding region of cP2X1. The hybridization
was performed in ExpressHyb solution (Clontech, Palo Alto, CA,
USA) at 68‡C for 1 h, the ¢nal wash was done in 0.1USSC,
0.1USDS at 65‡C. The membrane was exposed to an X-ray ¢lm for
three days.
2.3. Electrophysiological recordings
The full-length cP2X1 cDNA was subcloned into the mammalian
expression vector pcDNA3 (Invitrogen, Groningen, The Netherlands).
Chinese hamster ovary (CHO) cells were transfected, selected using 1
mg ml31 G418 (Sigma, St. Louis, MO, USA), cloned and maintained
using 0.5 mg ml31 G418 as previously described [23].
For electrophysiological measurements, both the amphotericin B
perforated patch con¢guration [24] and the whole-cell con¢guration
[25] of the patch-clamp technique were used. Recordings were made
with an EPC-9 ampli¢er and Pulse+Pulse¢t software package (HEKA
Elektronics, Lambrecht, Germany). All measurements were carried
out at room temperature. Pipette solution for perforated patch record-
ings contained (in mM): 120 K-gluconate, 20 KCl, 10 BAPTA, 10
HEPES, pH 7.2. Thin borosilicate pipettes (2.5^3 M6) were back¢lled
with the same solution containing 300 Wg ml31 amphotericin B (Sig-
ma, St. Louis, MO, USA; stock solution in DMSO, ¢nal DMSO
dilution 0.6%). For whole-cell recordings we used identical pipettes
¢lled with a solution containing (in mM): 120 K-gluconate, 20 mM
KCl, 2 mM MgCl2, 2 mM ATP, 5 mM EGTA, 10 mM HEPES,
pH 7.2. Extracellular solution contained (in mM): 140 NaCl, 2.8
KCl, 2 CaCl2, 10 HEPES, pH 7.2. Currents were low-pass ¢ltered
at 500 Hz and digitized at 2 kHz. Typical holding potential was
370 mV. Agonists dissolved at the appropriate concentration were
rapidly applied using a DAD-12 application system (ALA Scienti¢c
Instruments, Westbury, NY, USA). Antagonists were superfused for
5^10 min before being applied together with the agonist. All data
points are meanRS.E.M. of n determinations.
2.4. Drugs
ATP, KLmeATP, L,Q methylen-ATP (LQmeATP), UTP and suramin
were purchased from Sigma (St. Louis, MO, USA). 2-Methylthio-
ATP (2MeSATP) and PPADS were obtained from Tocris Cookson
(Bristol, UK). 8,8P-(Carbonylbis(imino-3,1-phenylene carbonylimino)-
bis(1,3,5-naphthalenetrisulfonic) acid) (NF023) was obtained from
Calbiochem (San Diego, CA, USA).
3. Results and discussion
PCR with degenerate oligonucleotides obtained from the
sequences of the known P2X receptors was used to PCR
cDNA obtained from chicken brain. A partial sequence of
approximately 740 bp was obtained and this sequence infor-
mation was used to clone a full-length cDNA from embryonic
chicken skeletal muscle and heart by 3P and 5P RACE-PCR.
The obtained cDNA is 1610 bp long, contains an open read-
ing frame preceded by a stop codon and encodes a protein of
392 amino acids (Fig. 1) with a calculated molecular weight of
44.5 kDa. This protein is around 65% identical to both rat
and human P2X1 [12,26] with signi¢cantly lower sequence
identity to other P2X receptor subunits, suggesting it is the
chicken orthologue of P2X1 (cP2X1). The identity is well dis-
tributed along the sequence except for the last amino acids of
the carboxy terminus (Fig. 1). Di¡erences in the primary se-
quence of the carboxy terminal domain between orthologues
have also been described for human, rat and chicken P2X5
subunits [9]. cP2X1 presents the two putative transmembrane
domains and the 10 cysteines in the extracellular loop that are
conserved for all P2X receptors. The disruption of disul¢de
bonds between cysteines by site-directed mutagenesis a¡ects
the tra⁄cking of human P2X1 receptor subunits to the plasma
Fig. 1. Alignment of chicken, human and rat P2X1 receptor subunits. Residues identical in all sequences are denoted by boxes. Squares: puta-
tive N-glycosylation sites [N-X-(S/T)] ; circle: putative PKC phosphorylation site conserved in all P2X subunits. Shaded boxes mark the trans-
membrane domains and the arrows indicate the position of the degenerate oligonucleotides used to isolate cP2X1. The sequence is in GenBank,
accession number AJ511278.
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membrane [27], indicating their importance for correct pro-
cessing of the protein. Additionally, three putative N-linked
glycosylation sites are present in the primary sequence (N78,
N155, N244), two of them (N155 and N244) are also present
in the hP2X1 sequence while only one putative N-glycosyla-
tion position (N155) is coincident with one of the four N-
glycosylated sites in the rP2X1 protein. Any two of those
four putative N-glycosylation sites must be glycosylated to
ensure fully functional expression of rP2X1 receptors [28],
explaining the lack of conservation of putative N-glycosylated
positions between orthologues.
To characterize the pharmacological and functional proper-
ties of cP2X1 receptors we transfected CHO cells with the
cP2X1 subunit. ATP evoked currents (1.4 R 0.2 nA for 10
WM ATP, n=26) that desensitized in the presence of the ago-
nist with a time constant of 203.9R 9.9 ms (n=20). Following
repeated applications at 8-min intervals in the whole-cell re-
cording con¢guration the peak currents declined, longer wash-
ing intervals (up to 30 min) had no e¡ect on the recovery of
the current (not shown). Run-down of the current most likely
results from the dialysis of the cell with the pipette solution
leading to the dilution of intracellular components. The same
phenomenon has been shown for native P2X receptors in
smooth muscle tissue and could be avoided by performing
Fig. 2. Agonist pro¢le of recombinant chicken P2X1 receptors. A: Whole-cell currents measured in the perforated patch con¢guration in re-
sponse to stimulation of cP2X1 receptors by various nucleotides at a concentration of 30 WM. The holding potential was 370 mV. B: Dose^re-
sponse curve for ATP. The continuous line for ATP is the ¢t to the data using the equation I= Imax/(1+(EC50/L)nH ), where I is the actual cur-
rent for a ligand concentration (L), nH is the Hill coe⁄cient and Imax is the maximal current: EC50 = 1.8R 0.2 WM, with a Hill coe⁄cient of
1.4R 0.2 (n=3^6). The amount of current obtained at each ATP concentration was normalized to the current obtained with 30 WMATP.
C: maximal currents elicited by 30WM ATP at di¡erent holding voltages (n=3). I^V steady state curve showing inward recti¢cation. Reversal
potential after correction for liquid junction potentials was 30.6 R 0.9 mV.
6
Fig. 3. Antagonist pro¢le of recombinant chicken P2X1 receptors.
A: Whole-cell currents measured in the perforated patch con¢gura-
tion upon application of 10 WM ATP in the absence and in the
presence of 10 WM NF023 or 1 WM PPADS. Both antagonist were
pre-applied for 10 min. The interval between ATP applications was
10 min. B: Percentage of block of the current elicited by 10 WM
ATP in the presence of di¡erent concentrations of the antagonists
suramin, NF023 or PPADS.
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the measurements in the perforated patch con¢guration of the
patch-clamp technique [29]. In fact, using the perforated patch
con¢guration we obtained reproducible responses by repeti-
tive applications of agonists at 8^10-min intervals. Represen-
tative currents obtained upon application of agonists are
shown in Fig. 2A. The rank order of agonist e⁄ciency (at
30 WM)was: ATPsBzBzATPs 2MeSATP=K,LmeATPs L,Q
meATPsUTP (n=3^7). Construction of a dose^response
curve for ATP gave an EC50 value of 1.8 R 0.2 WM, with a
Hill coe⁄cient of 1.4 R 0.2 (n=3^6) (Fig. 2B). The current^
voltage relationship for ATP-evoked P2X receptor currents
(Fig. 2C) was inwardly rectifying and reversed at 30.6R 0.9
mV after correcting for liquid junction potentials [30]. Addi-
tionally, we analyzed the sensitivity of cP2X1 to several P2
antagonists including suramin, NF023 and PPADS (Fig. 3).
Surprisingly, both suramin and NF023 were poor antagonists
at cP2X1 receptors compared to what has been described for
the mammalian orthologues [12,14,31]. Thus, 10 WM suramin
or NF023 blocked only 29.4 R 6.2% (n=11) or 22.8R 9.3%
(n=13) of the current evoked by 10 WM ATP (Fig. 3A,B).
Increasing the concentration of suramin and NF023 to 25 WM
produced a blockade of the current of 43.1R 9.7% (n=13) and
41.8R 10.8% (n=11), respectively. In order to compare this
data with the data obtained at mammalian orthologue recep-
tors under our measuring conditions, HEK cells transfected
with human P2X1 were measured. Suramin and NF023 were
e¡ective blockers of human P2X1 receptors (Fig. 4), with 1
WM of suramin or NF023 blocking approximately 90% of the
current elicited by 10 WM ATP (91.6 R 7.8 for NF023,
90.5R 7.8 for suramin, n=4). Human P2X1 receptors with
altered sensitivity to suramin have been obtained upon muta-
tion of several positively charged amino acids located at the
extracellular domain of the protein [32]. However, all ¢ve
amino acid residues (K70, K215, K309, R202 and R292 of
hP2X1) are conserved between human and chicken P2X1 sub-
units. In contrast, PPADS was an e¡ective antagonist at
cP2X1 receptors (IC50W1 WM, n=5) (Fig. 3A,B) in a compa-
rable way to what has been described for hP2X1 receptors
[14].
Northern blot hybridization analysis of mRNA isolated
from several chicken embryonic tissues (15-day-old embryos)
revealed the expression of a predominant transcript of 1.95 kb
with two more transcripts (2.2 and 2.8 kb) showing lower
abundance (Fig. 5). The highest level of expression was found
in lung. Transcripts were also detected in skeletal muscle, liver
and heart. Presence of transcripts of di¡erent length has also
been observed for rat P2X1 and has been attributed both to
the presence of 3P untranslated region of di¡erent length and
to the presence of incompletely spliced mRNA [12]. By North-
ern blot and in situ hybridization, cP2X4 and cP2X5 tran-
scripts were also found to be present in skeletal muscle,
with further overlapping expression in other embryonic tissues
(including heart and lung) [5,6,8,9,33]. Co-expression of rat
P2X1 and P2X5 subunits produced a heteromeric receptor
with speci¢c functional properties [34,35]. Moreover, hetero-
multimerization between rP2X4 and rP2X5 subunits has been
shown by co-immunoprecipitation although no functional
Fig. 4. Antagonist pro¢le of recombinant human P2X1 receptors.
A: Whole-cell currents measured in the perforated patch con¢gura-
tion upon application of 10 WM ATP in the absence and in the
presence of 10 WM NF023 or suramin. Both antagonists were pre-
applied for 10 min. The interval between ATP applications was 10
min. B: Percentage of block of the current elicited by 10 WM ATP
in the presence of di¡erent concentrations of the antagonists sura-
min and NF023.
Fig. 5. Chicken P2X1 transcript distribution in several chicken em-
bryonic tissues. Ten micrograms poly(A)þ mRNA were used per
lane. The length of the cP2X1 transcript is approximately 1.9 kb in
all tissues analyzed.
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characterization has been described so far [36]. Homomeric
cP2X5 receptors present most of the functional properties
observed in native skeletal muscle P2X receptors with the
exception of the response to KLmeATP [9,37]. Most likely
the native skeletal muscle P2X receptor in chicken is a hetero-
multimeric receptor that might be composed of P2X1, P2X4
and P2X5 subunits.
In summary, we have isolated a new P2X subunit that is the
chicken orthologue of mammalian P2X1 receptors. Run-down
of the current elicited by ATP at cP2X1 receptors could be
avoided by using the perforated patch con¢guration of the
patch-clamp technique. Agonists sensitivity was similar to
mammalian P2X1 receptors. However, cP2X1 receptors were
less sensitive to suramin and suramin analogs than the mam-
malian counterparts. The presence of cP2X1 transcripts in
skeletal muscle of chicken embryos could indicate a possible
heteromultimerization with the cP2X5 and the cP2X4 subunit.
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